AroCell
0,53
SEK
+6 %
Mindre end 1K følgere
AROC
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Finansielt overblik og estimater
Ownership
+6%
-9,4%
+35,9%
+29,9%
-6,19%
+52,3%
-1,85%
-46,79%
-77,76%
AroCell specializes in oncology and bacteriology. The company has a broad product portfolio, and develops, markets and sells blood and urine sample tests that are used by hospitals and clinics. The tests are intended to provide information for the detection of diseases such as urological cancers and typhoid fever. AroCell targets patient groups in different parts of the world. The head office is in Stockholm.
Læs mereMarkedsværdi
122,09 mio. SEK
Aktieomsætning
38,86 t SEK
Omsætning
57,44 mio.
EBIT %
-75,61 %
P/E
-
Udbytteafkast, %
-
Finanskalender
7.5
2025
Delårsrapport Q1'25
15.5
2025
Generalforsamling '25
21.8
2025
Delårsrapport Q2'25
Alle
Selskabsmeddelelser
ViserAlle indholdstyper
AroCell AB (publ) Interim Report January 1st to December 31st, 2024
New patent approval in China strengthens the AroCell patent portfolio
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools